Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

12 Nov 2015

Abstract excerpt

TP53 and ataxia telangiectasia mutated (ATM) defects are associated with genomic instability, clonal evolution, and chemoresistance in chronic lymphocytic leukemia (CLL). Currently, therapies capable of providing durable remissions in relapsed/refractory TP53- or ATM-defective CLL are lacking. Ataxia telangiectasia and Rad3-related (ATR) mediates response to replication stress, the absence of which leads to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26563132
DOI: 10.1182/blood-2015-05-644872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cellsPMID 26563132Read ↗

Targeting ATM-deficient CLL through interference with DNA repair pathwaysSemantic proximity Read ↗

A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.Semantic proximity Read ↗

Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR InhibitorsSemantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response Pathways in TP53 - and ATM -Mutated TumorsSemantic proximity Read ↗

ATM and ATR as therapeutic targets in cancerSemantic proximity Read ↗

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell LymphomasSemantic proximity Read ↗

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML.Semantic proximity Read ↗

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisibSemantic proximity Read ↗

Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastomaSemantic proximity Read ↗

Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma CellsSemantic proximity Read ↗

A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 BlockadeSemantic proximity Read ↗

DNA damage pathways and B-cell lymphomagenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.